[go: up one dir, main page]

DE68929550D1 - Im wesentlichen reines, vollständiges ospa protein, frei von anderen b. burgdorferi bestandteilen - Google Patents

Im wesentlichen reines, vollständiges ospa protein, frei von anderen b. burgdorferi bestandteilen

Info

Publication number
DE68929550D1
DE68929550D1 DE68929550T DE68929550T DE68929550D1 DE 68929550 D1 DE68929550 D1 DE 68929550D1 DE 68929550 T DE68929550 T DE 68929550T DE 68929550 T DE68929550 T DE 68929550T DE 68929550 D1 DE68929550 D1 DE 68929550D1
Authority
DE
Germany
Prior art keywords
components
pellet
supernatant
fraction
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68929550T
Other languages
English (en)
Other versions
DE68929550T2 (de
Inventor
Sven Bergstroem
Alan George Barbour
Louis A Magnarelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symbicom AB
Original Assignee
Symbicom AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8146053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68929550(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Symbicom AB filed Critical Symbicom AB
Publication of DE68929550D1 publication Critical patent/DE68929550D1/de
Application granted granted Critical
Publication of DE68929550T2 publication Critical patent/DE68929550T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE68929550T 1988-10-24 1989-10-24 Im Wesentlichen reines ganzes OspaA-Protein, frei von anderen B. burgdorferi-Materialien Expired - Lifetime DE68929550T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK590288A DK590288D0 (da) 1988-10-24 1988-10-24 Kemiske forbindelser
DK590288 1988-10-24

Publications (2)

Publication Number Publication Date
DE68929550D1 true DE68929550D1 (de) 2007-03-08
DE68929550T2 DE68929550T2 (de) 2007-12-06

Family

ID=8146053

Family Applications (4)

Application Number Title Priority Date Filing Date
DE68929565T Expired - Lifetime DE68929565D1 (de) 1988-10-24 1989-10-24 Borrelia burgdorferi OspA Polypeptid zur Immunisierung gegen Lymeborreliose
DE68929369T Expired - Lifetime DE68929369T2 (de) 1988-10-24 1989-10-24 DNS Fragmente, die für Borrelia burgdorferi OspA kodieren, Verfahren zur Herstellung von OspA Polypeptiden, und diagnostische Verfahren basierend auf diesen DNS Fragmenten
DE68927891T Expired - Lifetime DE68927891T2 (de) 1988-10-24 1989-10-24 Fraktionen von BORELLA BURGDORFERI mit immunogener Wirkung
DE68929550T Expired - Lifetime DE68929550T2 (de) 1988-10-24 1989-10-24 Im Wesentlichen reines ganzes OspaA-Protein, frei von anderen B. burgdorferi-Materialien

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DE68929565T Expired - Lifetime DE68929565D1 (de) 1988-10-24 1989-10-24 Borrelia burgdorferi OspA Polypeptid zur Immunisierung gegen Lymeborreliose
DE68929369T Expired - Lifetime DE68929369T2 (de) 1988-10-24 1989-10-24 DNS Fragmente, die für Borrelia burgdorferi OspA kodieren, Verfahren zur Herstellung von OspA Polypeptiden, und diagnostische Verfahren basierend auf diesen DNS Fragmenten
DE68927891T Expired - Lifetime DE68927891T2 (de) 1988-10-24 1989-10-24 Fraktionen von BORELLA BURGDORFERI mit immunogener Wirkung

Country Status (10)

Country Link
US (6) US5523089A (de)
EP (4) EP1092774B1 (de)
AT (3) ATE212376T1 (de)
AU (1) AU639667B2 (de)
CA (1) CA2001328C (de)
DE (4) DE68929565D1 (de)
DK (3) DK590288D0 (de)
FI (1) FI112366B (de)
NO (1) NO911602L (de)
WO (1) WO1990004411A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US6054296A (en) * 1988-10-24 2000-04-25 Symbicom Ab 66 kDa antigen from Borrelia
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US6300101B1 (en) 1988-10-24 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions including a 13kD B. burgdorferi protein
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
ZA907419B (en) * 1989-09-19 1991-07-31 Max Planck Gesellschaft Vaccine against lyme disease
US5470712A (en) * 1990-03-05 1995-11-28 Us Health Antigenic proteins of Borrelia burgdorferi
SG47447A1 (en) * 1990-06-15 1998-04-17 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
IE912303A1 (en) * 1990-07-06 1992-01-15 American Home Prod Vaccine against lyme disease and a challenge model for¹evaluating vaccine efficiency
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US5436000A (en) * 1991-01-11 1995-07-25 University Of Texas System Flagella-less borrelia
KR940701542A (ko) * 1991-06-13 1994-05-28 유진 팬 특이성 리간드를 검출하기 위한 분석법
US5324630A (en) * 1991-06-28 1994-06-28 The Regents Of The University Of California Methods and compositions for diagnosing lyme disease
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
AU666326B2 (en) * 1991-08-15 1996-02-08 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Osp A proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
AU676140B2 (en) * 1991-10-18 1997-03-06 Connaught Laboratories Inc. Preparation of recombinant borrelia proteins
ATE234365T1 (de) * 1991-10-22 2003-03-15 Symbicom Ab Verbesserungen der diagnose und der prophylaxe von borrelia burgdorferi
US5618533A (en) * 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5308753A (en) * 1992-02-20 1994-05-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for purifying and detecting IGM antibodies
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
BE1006728A3 (fr) * 1993-02-19 1994-11-29 Wallone Region Sondes d'acides nucleiques specifiques au spirochete borrelia burgdorferi.
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US6716591B1 (en) 1993-07-30 2004-04-06 Yale University B. burgdorferi polypeptides
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
DE69535059T2 (de) * 1994-04-11 2007-01-18 Wyeth Holdings Corp. Borrelia burgdorferi bacterin
US6087097A (en) * 1994-05-12 2000-07-11 Mayo Foundation For Medical Education And Research PCR detection of Borrelia burgdorferi
US6312907B1 (en) 1995-04-24 2001-11-06 The Texas A & M University System DbpA compositions and methods of use
US6214355B1 (en) 1995-04-24 2001-04-10 Texas A & M University System DbpA compositions
US6248517B1 (en) 1995-04-24 2001-06-19 The Texas A & M University System Decorin binding protein compositions and methods of use
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
US6251405B1 (en) 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
CA2223433C (en) * 1995-06-07 2003-11-18 Amgen Inc. Ob protein compositions and methods
ZA964896B (en) 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
US6045804A (en) * 1996-03-07 2000-04-04 Mayo Foundation For Medical Educational Research Method for detecting B. burgdorferi infection
CA2253834A1 (en) * 1996-05-08 1997-11-13 Yale University B. burgdorferi polypeptides expressed in vivo
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
EP0979101B1 (de) 1996-07-03 2010-10-27 Merial, Inc. Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
DE19632862B4 (de) * 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
US6368603B1 (en) 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
EP1009859A1 (de) * 1997-06-20 2000-06-21 Human Genome Sciences Impfstoff gegen die lyme-krankheit
US6902893B1 (en) * 1997-06-20 2005-06-07 Gil H. Choi Lyme disease vaccines
WO1999000413A1 (en) 1997-06-30 1999-01-07 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6610838B1 (en) 1997-09-10 2003-08-26 Symbicom Aktiebolag P13 antigens from Borrelia
CA2300365A1 (en) * 1997-09-10 1999-03-18 Symbicom Aktiebolag P13 antigens from borrelia
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
GB9811219D0 (en) * 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
US6475492B1 (en) 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
US6592875B1 (en) * 1999-06-21 2003-07-15 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
US6689364B2 (en) * 2000-03-21 2004-02-10 Tufts University Borrelia burgdorferi polypeptides and uses thereof
US7396675B2 (en) * 2000-06-02 2008-07-08 Bayer Technology Services Gmbh Kit and method for determining a plurality of analytes
WO2002016421A2 (en) 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
US20040033623A1 (en) * 2002-08-16 2004-02-19 Igenex, Inc. Assay for detection of antigen in bodily fluid
WO2004103269A2 (en) * 2002-10-18 2004-12-02 Macrogenics, Inc. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
DE602004019063D1 (de) * 2003-04-02 2009-03-05 Us Gov Health & Human Serv Cholesterol enthaltende verbindungen und deren verwendung als immunogen gegen borellia burgdorferi
US20060051060A1 (en) * 2003-07-03 2006-03-09 Henry Dorovanessian Method and system for digitally recording broadcast content
WO2006026248A1 (en) 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
US20060281139A1 (en) * 2005-05-23 2006-12-14 Viramed Biotech Ag Carrier and method for the detection of anti-borrelia antibodies and test kit for use in the diagnosis of Lyme borreliosis infections
US7663212B2 (en) 2006-03-21 2010-02-16 Infineon Technologies Ag Electronic component having exposed surfaces
US7541681B2 (en) * 2006-05-04 2009-06-02 Infineon Technologies Ag Interconnection structure, electronic component and method of manufacturing the same
JP5177824B2 (ja) 2006-11-03 2013-04-10 シェーリング−プラウ・リミテッド イヌのライム病のワクチン
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3023436A1 (de) 2007-07-03 2016-05-25 Dako Denmark A/S Verbesserte verfahren zur herstellung, markierung und verwendung von mhc-multimeren
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US20110117131A1 (en) * 2008-04-09 2011-05-19 Ning Huang Production of OspA for Lyme Disease Control
US20110280930A1 (en) 2008-05-02 2011-11-17 Facundo Batista Products and methods for stimulating an immune response
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US20130011424A1 (en) 2010-03-09 2013-01-10 Timur ARTEMEV Polyepitope constructs and methods for their preparation and use
BR112012027315B1 (pt) 2010-05-14 2021-08-17 Baxalta Incorporated Polipeptídeo, composição, molécula de ácido nucleico, vetor, microrganismo transgênico, processo de produção de um polipeptídeo, vacina combinada, e, uso de uma composição ou de uma vacina combinada
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
JP2013539032A (ja) 2010-09-27 2013-10-17 コーネル ユニバーシティ ライム病の診断方法
WO2012047970A1 (en) * 2010-10-05 2012-04-12 Board Of Trustees Of Michigan State University Regulatory factors controlling oil biosynthesis in microalgae and their use
CN104640563A (zh) 2012-07-27 2015-05-20 巴克斯特国际公司 包含嵌合的ospa分子的组合物及其使用方法
US10669567B2 (en) 2015-02-17 2020-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High sensitivity method for early Lyme disease detection
NZ747144A (en) 2016-04-14 2024-12-20 Genzyme Corp Multi-dose compositions containing an antimicrobial polyamide or octenidine preservative
WO2018227109A1 (en) 2017-06-08 2018-12-13 Colorado State University Research Foundation Differentiation of lyme disease and southern tick-associated rash illness
EP3898666A2 (de) 2018-12-17 2021-10-27 Immudex ApS Panel mit borrelia-mhc-multimeren
KR20250035053A (ko) 2022-06-07 2025-03-11 리제너론 파아마슈티컬스, 인크. T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도
EP4536836A1 (de) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotypisierte virale partikel zum targeting von tcr-exprimierenden zellen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US4888276A (en) * 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
DE4015911A1 (de) 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit

Also Published As

Publication number Publication date
DK200401413A (da) 2004-09-17
EP0711563B1 (de) 2007-01-17
NO911602L (no) 1991-06-24
EP0445135B1 (de) 1997-03-19
EP0565208A1 (de) 1993-10-13
AU4495389A (en) 1990-05-14
EP1092774A3 (de) 2001-04-25
EP0711563A1 (de) 1996-05-15
EP0445135A1 (de) 1991-09-11
ATE212376T1 (de) 2002-02-15
CA2001328C (en) 2005-12-13
US6203798B1 (en) 2001-03-20
FI911964A0 (fi) 1991-04-23
EP1092774A2 (de) 2001-04-18
US5688512A (en) 1997-11-18
DE68929550T2 (de) 2007-12-06
DE68927891D1 (de) 1997-04-24
ATE150318T1 (de) 1997-04-15
DK75091A (da) 1991-06-12
US5582990A (en) 1996-12-10
DE68929369D1 (de) 2002-03-14
EP1092774B1 (de) 2009-06-03
DK590288D0 (da) 1988-10-24
ATE432988T1 (de) 2009-06-15
AU639667B2 (en) 1993-08-05
CA2001328A1 (en) 1991-04-24
DK175844B1 (da) 2005-03-29
FI112366B (fi) 2003-11-28
US6183986B1 (en) 2001-02-06
DE68929565D1 (de) 2009-07-16
WO1990004411A1 (en) 1990-05-03
NO911602D0 (no) 1991-04-23
DE68927891T2 (de) 1997-10-02
US5523089A (en) 1996-06-04
DE68929369T2 (de) 2002-09-26
EP0565208B1 (de) 2002-01-23
DK75091D0 (da) 1991-04-23
US6083722A (en) 2000-07-04

Similar Documents

Publication Publication Date Title
DE68929550D1 (de) Im wesentlichen reines, vollständiges ospa protein, frei von anderen b. burgdorferi bestandteilen
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
ATE294864T1 (de) Äusseres membranprotein von haemophilus
IL57491A (en) Recombinant dna,methods for the production thereof and proteins or polypeptides produced thereby
WO2000073316A3 (en) Virus immunologic determinants
KR970707153A (ko) 카텝신 02 프로테아제(cathepsin 02 protease)
DE50013610D1 (de) Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
DE3369466D1 (en) Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
EP0370458A3 (de) Von synthetischer DNS abgeleitete rekombinante HIV-1-Antigene
ATE292981T1 (de) Tat transdominante variante aus human immunodeficiency virus
ATE387458T1 (de) Fas-antigenbindender ligand
FR2669338B1 (de)
CA2093427A1 (en) Molecular clones of hiv-1 and uses thereof
EP0331356A3 (de) Expression von HIV-bindenden Proteinen
Takenaka et al. Royal jelly from Apis cerana japonica and Apis mellifera
PL318443A1 (en) Cells possessing alluring receptors cd4 as well as appropriate molecules and methods
Lee-Huang A new preparative method for isolation of human erythropoietin with hydrophobic interaction chromatography
Reeves et al. Partial purification and characterization of the multiple molecular forms of staphylococcal clotting activity (coagulase)
Hamazaki et al. Comparative studies of human, equine, porcine and bovine erythrocyte membrane sialoglycoproteins
ES2059823T3 (es) Metodos y sistemas para producir antigenos de hiv.
WO2023178187A3 (en) Methods and compositions comprising fusion proteins for improved immunotherapies
WO1997026361A3 (en) Bacterial donor cell useful in conjugation
RU96124779A (ru) Днк, кодирующая кератиназу bacilus licheniformis pwd-1
Grunberg et al. Blood group NN-dependent phagocytosis mediated by NFA-3 haemagglutinin of Escherichia coli
SE9404066D0 (sv) Fusion proteins of immunopotentiating activity

Legal Events

Date Code Title Description
8364 No opposition during term of opposition